← Back to Search

Glucagon-Like Peptide-2 (GLP-2) Analog

glepaglutide for Short Bowel Syndrome (EASE SBS 1 Trial)

Phase 3
Waitlist Available
Research Sponsored by Zealand Pharma
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 20 and 24 weeks
Awards & highlights

EASE SBS 1 Trial Summary

This trial is testing whether glepaglutide is effective in reducing the amount of parenteral support (intravenous feeding) required by patients with short bowel syndrome.

Eligible Conditions
  • Short Bowel Syndrome

EASE SBS 1 Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~20 and 24 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 20 and 24 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in weekly Parenteral Support (PS) volume
Secondary outcome measures
Change in PS volume per week
Clinical response in PS volume
Days off PS
+10 more

EASE SBS 1 Trial Design

3Treatment groups
Experimental Treatment
Placebo Group
Group I: Glepaglutide SC injections twice weeklyExperimental Treatment1 Intervention
Intervention: Glepaglutide
Group II: Glepaglutide SC injections once weekly and placebo once weeklyExperimental Treatment2 Interventions
Intervention: Glepaglutide
Group III: Placebo SC injections twice weeklyPlacebo Group1 Intervention
Intervention: Placebo
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Placebo
1995
Completed Phase 3
~2670
glepaglutide
2018
Completed Phase 3
~110

Find a Location

Who is running the clinical trial?

Zealand PharmaLead Sponsor
37 Previous Clinical Trials
2,672 Total Patients Enrolled
4 Trials studying Short Bowel Syndrome
304 Patients Enrolled for Short Bowel Syndrome
Study DirectorStudy DirectorZealand Pharma
1,206 Previous Clinical Trials
489,548 Total Patients Enrolled
22 Trials studying Short Bowel Syndrome
3,297 Patients Enrolled for Short Bowel Syndrome

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Efficacy And Safety Evaluation of Glepaglutide in Treatment of Short Bowel Syndrome (SBS)
2018. "Efficacy And Safety Evaluation of Glepaglutide in Treatment of Short Bowel Syndrome (SBS)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03690206.
~16 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top